You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Oestrogen plus progestin was not effective for long term secondary prevention of coronary heart disease in postmenopausal women

Article Text

Article menu
Download PDFPDF
Therapeutics
Oestrogen plus progestin was not effective for long term secondary prevention of coronary heart disease in postmenopausal women

https://doi.org/10.1136/ebm.8.1.12

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2002) JAMA 288, 49; Grady D, Herrington D, Bittner V, et al.. , for the HERS Research Group. . Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).. ;. :. –57..
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In postmenopausal women with established coronary heart disease (CHD), does oestrogen plus progestin reduce the risks of CHD events after 6.8 years of follow up?

    Design

    Randomised (allocation concealed*), placebo controlled trial. The study was blinded (patients, investigators, and outcome assessors)* for the initial mean 4.1 years of follow up and unblinded* for the subsequent mean 2.7 years of follow up (the latter 2.7 years was the HERS II study).

    Setting

    20 US outpatient and community centres.

    Patients

    2763 postmenopausal women <80 years of age (mean age 67 y) with established CHD who had not had a hysterectomy. Of those alive at 4.1 years (n=2510), follow up was 84% at 6.8 years.

    Intervention

    Women were allocated to conjugated oestrogen, 0.625 mg/day, plus medroxyprogesterone acetate, 2.5 mg/day (n=1380), or placebo (n=1383) for 4.1 years. In the subsequent 2.7 years (during HERS II), 1156 women in the oestrogen plus progestin group and 1165 women in the placebo group continued follow …

    View Full Text